Clinical Trial

A Study to Evaluate the Safety, Tolerability and PK of SK-09

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This Phase 1 trial consists of two parts: Part 1 is a Single Ascending Dose (SAD) study, and Part 2 is a Multiple Ascending Dose (MAD) study. Both parts adopt a randomized, double-blind, placebo-controlled design.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-08-31 -> 2026-10-04 2026-06-06
minor Completion pushed: 2026-08-31 -> 2026-10-04 2026-06-06
Trial Details
NCT Number NCT07267026
Lead Sponsor Consun Pharmaceutical Group
Conditions FSGS, MCD
Enrollment 72 participants
Start Date 2025-12-08
Primary Completion 2026-10-04 (estimated)
Study Completion 2026-10-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-05